Clinical Trials

Numerous clinical trials investigate mupirocin across Phase 1 through Phase 4, early phase, and unclassified interventional designs. These studies primarily target *Staphylococcus aureus* infections, general staphylococcal colonization, peritoneal dialysis-related infections, maternal-infant transmission, and neonatal decolonization interventions. Sponsored by academic centers—such as Johns Hopkins University and Duke University—as well as commercial entities like Destiny Pharma Plc, trial recruitment statuses range from active and recruiting to completed.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07142408 RECRUITING
Surgical Wound Infection
The Cooper Health System
 2023-03-13 PHASE3
NCT06712433 NOT_YET_RECRUITING
Sarcoma,Soft Tissue
Adam Olson
 2026-09-30 PHASE2
NCT07524894 NOT_YET_RECRUITING
Radiation Mucositis; Staphylococcal Aureus Infection; Head and Neck Cancer
David Palma
 2026-06-01 PHASE2
NCT06805994 RECRUITING
Staphylococcal Aureus Infection; Microbial Colonization; Pediatric Infection; S. Aureus Colonization; Microbial Transplant
Johns Hopkins University
 2025-08-27 PHASE1
NCT07635433 NOT_YET_RECRUITING
Chronic Rhinosinusitis With Nasal Polyps
The First Affiliated Hospital of Xinxiang Medical College
 2026-07-01 EARLY_PHASE1
NCT05586776 RECRUITING
Surgical Site Infection
University of California, Irvine
 2023-01-17 PHASE4
NCT06633588 COMPLETED
Staphylococcus Aureus; Colonization, Asymptomatic
Swiss Paraplegic Research, Nottwil
 2025-05-01 PHASE4
NCT06210594 COMPLETED
Staphylococcus Aureus Infection
Johns Hopkins Bloomberg School of Public Health
 2024-04-01 PHASE4
NCT03489629 COMPLETED
Cystic Fibrosis
University of North Carolina, Chapel Hill
 2018-04-03 PHASE2
NCT06368856 ACTIVE_NOT_RECRUITING
Healthy; Staphylococcus Aureus Infection
Centre Hospitalier Universitaire de Saint Etienne
 2024-02-29 PHASE1
NCT02572791 COMPLETED
Skin and Subcutaneous Tissue Bacterial Infections; Staphylococcus Aureus; MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Washington University School of Medicine
 2015-10 PHASE4
NCT06541145 COMPLETED
Bacterial Colonization
Duke University
 2024-08-21
NCT07064161 COMPLETED
Biopsy Wound
University of Santo Tomas Hospital, Philippines
 2024-01-29
NCT05893810 UNKNOWN
Nasopharyngeal Carcinoma; Radiation-induced Oral Mucositis; Bacterial Colonization; Quality of Life
Jiangxi Provincial Cancer Hospital
 2023-07-01 PHASE3
NCT03140423 COMPLETED
Staphylococcus Aureus
Harvard Pilgrim Health Care
 2017-05-01 PHASE4
NCT06291181 COMPLETED
Staphylococcus Aureus
Sohag University
 2023-01-01
NCT06046937 COMPLETED
Bacterial Infections
Victoriano Luna Medical Center
 2023-06-01 EARLY_PHASE1
NCT05874219 COMPLETED
Hemodialysis Complication; Hemodialysis Catheter Infection
Future University in Egypt
 2023-04-10 PHASE2; PHASE3
NCT05251584 UNKNOWN
Peritoneal Dialysis-related Infection
Phramongkutklao College of Medicine and Hospital
 2021-12-01
NCT06291181 Completed
Staphylococcus Aureus
Sohag University
 2023-01-01 Not Applicable
NCT05839158 COMPLETED
Wound Heal
Nanfang Hospital, Southern Medical University
 2022-03-01
NCT03883828 COMPLETED
Radiation Dermatitis
Montefiore Medical Center
 2019-06-03 PHASE2; PHASE3
NCT05251584 Unknown status
Peritoneal Dialysis-related Infection
Phramongkutklao College of Medicine and Hospital|Silpakorn University
 2021-12-01 Not Applicable
NCT03173053 TERMINATED
Staphylococcus Aureus; Motility Disorder
Radboud University Medical Center
 2018-02-08
NCT02547103 UNKNOWN
End Stage Renal Disease; Peritoneal Dialysis
Chiang Mai University
 2016-06-01 PHASE4
NCT04155203 COMPLETED
Secondarily Infected Traumatic Skin Lesions
Padagis LLC
 2019-10-15 PHASE3
NCT02216227 COMPLETED
Surgical Site Infection
VA Office of Research and Development
 2014-04-01
NCT03673956 COMPLETED
Chronic Rhinosinusitis (Diagnosis)
Mayo Clinic
 2018-09-26 PHASE1; PHASE2
NCT04047914 COMPLETED
Photochemotherapy; Renal Insufficiency, Chronic
University of Nove de Julho
 2019-11-01
NCT02127658 TERMINATED
MRSA
Indiana University
 2016-02-18 PHASE4
NCT01438515 COMPLETED
Methicillin-resistant Staphylococcus Aureus
Horizon Health Network
 2008-08
NCT02967432 COMPLETED
Staphylococcus
Crouse Hospital
 2016-10 PHASE2
NCT02223520 COMPLETED
Staph Aureus Colonization; Staph Aureus Infection
Johns Hopkins University
 2014-11
NCT03304873 COMPLETED
MRSA
NYU Langone Health
 2017-12-01 PHASE3
NCT03685487 Completed
Staphylococcus Aureus
Centre Hospitalier Universitaire de Saint Etienne
 2019-02-12 --
NCT02619773 COMPLETED
Surgical Site Infections
Gundersen Lutheran Medical Foundation
 2015-11
NCT02566928 UNKNOWN
Methicillin-Resistant Staphylococcus Aureus; Recurrence; Staphylococcal Skin Infections; Antibiotic Resistance
Clinical Directors Network
 2015-10 PHASE4
NCT01594827 COMPLETED
Cystic Fibrosis
Johns Hopkins University
 2012-10 PHASE2
NCT02560155 COMPLETED
Orthopedic Disorders; Surgical Site Infection
Lindenhofgruppe AG
 2015-11
NCT03081962 UNKNOWN
Surgical Site Infection
Hospital General Universitario Elche
 2017-02-15 PHASE3
NCT02963129 UNKNOWN
Hereditary Hemorrhagic Telangiectasia; Epistaxis
Hospital Italiano de Buenos Aires
 2017-06 PHASE3
NCT00631566 COMPLETED
HIV Infections; Staphylococcal Infections
Henry M. Jackson Foundation for the Advancement of Military Medicine
 2007-05
NCT02029872 COMPLETED
MRSA
Johns Hopkins University
 2014-01 PHASE4
NCT01814371 COMPLETED
Staphylococcal Skin Infection; Abscess; Furunculosis; Staphylococcus Aureus; MRSA Infection
Washington University School of Medicine
 2013-04
NCT04287777 COMPLETED
Impetigo
Reig Jofre Group
 2014-02 PHASE3
NCT02967432 Completed
Staphylococcus
Crouse Hospital|Jana Shaw MD|Steven Gross MD|David Martin RN|Dale Franz RPh|Rachel Carey
 2016-10 Phase 2
NCT01827358 COMPLETED
Staphylococcal Infection
National Institute of Allergy and Infectious Diseases (NIAID)
 2014-04-30 PHASE2
NCT04218799 COMPLETED
Human Microbiome
University of Maryland, Baltimore
 2014-08-12 PHASE4
NCT01943136 UNKNOWN
Impetigo
Philippine Dermatological Society
 2013-08 PHASE1
NCT02218307 COMPLETED
Chronic Rhinosinusitis
University of Miami
 2011-11 PHASE4
NCT01269541 COMPLETED
Throatcarriers of MRSA
Region Skane
 2011-03-01
NCT01349192 TERMINATED
Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
University of North Carolina, Chapel Hill
 2011-04 PHASE2
NCT04222699 COMPLETED
Human Microbiome
VA Office of Research and Development
 2012-09-18 PHASE4
NCT02284555 COMPLETED
Staphylococcal Infection
Destiny Pharma Plc
 2014-08 PHASE4
NCT00751374 UNKNOWN
Rate of Exit Site Infection; Rate of Atypical Mycobacterial Infection; Rate of Peritoneal Dialysis
Kwong Wah Hospital
 2008-09 PHASE4
NCT01152593 UNKNOWN
Surgical Wound Infection; Cesarean Section; Staphylococcus Aureus
Hillel Yaffe Medical Center
 2010-07
NCT01876550 COMPLETED
Secondarily Infected Traumatic Skin Lesions
Sun Pharmaceutical Industries, Inc.
 2013-02 PHASE1
NCT01408056 WITHDRAWN
Infantile Hemangiomas
Children's Hospital of Philadelphia
 2011-02 PHASE2
NCT01820455 COMPLETED
MRSA Colonization
University of Tennessee
 2012-01
NCT02267122 COMPLETED
Incisional Surgical Site Infections
Hospital General Universitario Elche
 2012-01 PHASE3
NCT01537783 COMPLETED
Cutaneous Abscess
Tufts Medical Center
 2011-09 PHASE4
NCT01949935 COMPLETED
Surgical Site Infections
Horizon Health Network
 2009-03 PHASE3
NCT01313182 COMPLETED
Surgical Site Infection
Solventum US LLC
 2011-03 PHASE4
NCT00108160 COMPLETED
Staphylococcal Infections
US Department of Veterans Affairs
 2005-04 PHASE4
NCT00560599 COMPLETED
Methicillin Resistant Staphylococcus Aureus Skin Infections
loren g miller
 2007-04 PHASE3
NCT01400308 TERMINATED
MRSA - Methicillin Resistant Staphylococcus Aureus Infection; MRSA Colonization
B. Braun Medical SA
 2010-02 PHASE4
NCT01918813 COMPLETED
Inflammatory Bowel Disease; Hepatobiliary Disease; Pancreas Disease
Chikara Tashiro
 2009-11
NCT00980980 COMPLETED
Methicillin-resistant Staphylococcus Aureus
Harvard Pilgrim Health Care
 2009-09
NCT00179959 COMPLETED
Atopic Dermatitis
Northwestern University
 2005-09 PHASE4
NCT00731783 COMPLETED
Staphylococcal Skin Infections; Abscesses; Furunculosis; Staphylococcus Aureus; MRSA Infection
Washington University School of Medicine
 2008-07
NCT01049438 COMPLETED
Methicillin Resistant Staphylococcus Aureus Skin Infections
Natividad Medical Center
 2006-08
NCT00513799 COMPLETED
Abscesses; Furunculosis; Staphylococcus Aureus; Staphylococcal Skin Infections
Washington University School of Medicine
 2007-03
NCT00400595 COMPLETED
End Stage Renal Disease
University Health Network, Toronto
 2006-02 PHASE4
NCT00626795 COMPLETED
Impetigo; Secondarily Infected Traumatic Lesions
LEO Pharma
 2008-02 PHASE2
NCT00713674 WITHDRAWN
Methicillin-Resistant Staphylococcus Aureus
Mercy Research
 2008-03
NCT00406913 COMPLETED
Endophthalmitis; Cataract Surgery; Prophylaxis
University of Chicago
 2005-10
NCT00801879 COMPLETED
Staphylococcus Aureus; HIV Infections
Columbia University
 2003-09 PHASE4
NCT00156377 COMPLETED
Cross Infection; Staphylococcal Infections
University Hospital Muenster
 2002-11 PHASE4
NCT00289588 COMPLETED
Community-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis
Brooke Army Medical Center
 2005-01

(data from https://clinicaltrials.gov, updated on 2025-08-26)

Check the Mupirocin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, blocking the incorporation of isoleucine into transfer RNA and effectively arresting bacterial protein synthesis. This metabolic disruption leads to inhibition of cellular growth and bacterial cell death, which underpins its clinical utility in treating Staphylococcus aureus infections and reducing bacterial skin colonization.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.